Health Care • Biotechnology: Pharmaceutical Preparations
$3.59 ▼ -0.04
(-1.10%)
MKT CAP: $715.9M • VOL: 3.33M
52W L $3 52W H $22
WVE // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $42.7M | $108.3M | $113.3M |
| YoY Revenue Growth % | -60.5% | -4.4% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$215.4M | -$110.4M | -$68.0M |
| Operating Margin % | -80.0% | -80.0% | -60.0% |
| Net Income (GAAP) | -$204.4M | -$97.0M | -$57.5M |
| EBITDA (Normalized) | -$214.8M | -$109.7M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$187.5M | -$151.0M | -$19.4M |
| Capital Expenditures (CapEx) | $718.0K | $938.0K | — |
| Free Cash Flow (FCF) | -$188.2M | -$152.0M | -$19.4M |
| FCF Margin % | -80.0% | -80.0% | -17.1% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $602.1M | $302.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $518.4M | $209.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR WVE.